Clinical Focus: Advances in the Treatment of Diabetes

It must be emphasized that although the loss of beta-cell function over time was minimized with rosiglitazone, it still occurred. This may be a function of starting the drug too late in the course of the decline of the beta cell, or it may simply reflect how little can be achieved with monotherapy. It is possible that initial dual therapy, even with HbAIc of less than 7%, may do an even better job ot preventing beta-cell deterioration.